Dare Bioscience Inc (DARE): Next-Year EPS Estimate 49.30%
As of 2026-06-18, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 49.30%. Featured in 2 EPS revision reports, most recently on 2026-04-20.
On 2026-05-19, analyst consensus for DARE's next-year EPS growth shifted from 45.45% to 49.30% — a positive change of 3.85 percentage points. The revised estimate has been sustained across 23 subsequent trading sessions. Current-year growth is projected at 21.11%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 49.30%
- EPS growth this year
- 21.11%
- EPS next quarter (est)
- -$0.30
- Last price
- $2.17
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-18 | 49.30% | 21.11% | -$0.30 | $2.17 |
| 2026-06-17 | 49.30% | 21.11% | -$0.30 | $2.08 |
| 2026-06-16 | 49.30% | 21.11% | -$0.30 | $2.11 |
| 2026-06-15 | 49.30% | 21.11% | -$0.30 | $1.98 |
| 2026-06-14 | 49.30% | 21.11% | -$0.30 | $2.02 |
| 2026-06-11 | 49.30% | 21.11% | -$0.30 | $2.03 |
| 2026-06-10 | 49.30% | 21.11% | -$0.30 | $2.00 |
| 2026-06-09 | 49.30% | 21.11% | -$0.30 | $1.92 |
| 2026-06-08 | 49.30% | 21.11% | -$0.30 | $1.85 |
| 2026-06-07 | 49.30% | 21.11% | -$0.30 | $1.88 |
| 2026-06-04 | 49.30% | 21.11% | -$0.30 | $2.18 |
| 2026-06-03 | 49.30% | 21.11% | -$0.30 | $2.05 |
| 2026-06-02 | 49.30% | 21.11% | -$0.30 | $2.14 |
| 2026-06-01 | 49.30% | 21.11% | -$0.30 | $2.19 |
| 2026-05-31 | 49.30% | 21.11% | -$0.30 | $2.23 |
| 2026-05-28 | 49.30% | 21.11% | -$0.30 | $2.28 |
| 2026-05-27 | 49.30% | 21.11% | -$0.30 | $2.33 |
| 2026-05-26 | 49.30% | 21.11% | -$0.30 | $2.34 |
| 2026-05-25 | 49.30% | 21.11% | -$0.30 | $2.37 |
| 2026-05-24 | 49.30% | 21.11% | -$0.30 | $2.37 |
| 2026-05-21 | 49.30% | 21.11% | -$0.30 | $2.41 |
| 2026-05-20 | 49.30% | 21.11% | -$0.30 | $2.33 |
| 2026-05-19 | 49.30% | 21.11% | -$0.30 | $2.25 |
| 2026-05-18 | 45.45% | 20.56% | -$0.31 | $2.11 |
| 2026-05-17 | 45.45% | 20.56% | -$0.31 | $2.17 |
| 2026-05-14 | 51.24% | -0.83% | -$0.30 | $2.86 |
| 2026-05-13 | 51.24% | -0.83% | -$0.30 | $2.82 |
| 2026-05-12 | 51.24% | -0.83% | -$0.30 | $2.63 |
| 2026-05-11 | 51.24% | -0.83% | -$0.30 | $2.52 |
| 2026-05-10 | 51.24% | -0.83% | -$0.30 | $2.75 |
Reports Featuring DARE
Recent News
- Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswire
- Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...GuruFocus.com
- Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To ExpectGuruFocus.com
Screen Performance
Aggregate stats across all 1795 tickers our top-EPS-revision screen has flagged over the past 78 days.
- Median return since detection
- +3.6%
- % of tickers in the green
- 58%
- Median return on winners
- +19.9%
- Large revisions captured
- 842
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Dare Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-06-18, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 49.30%, based on analyst consensus.
When was the latest EPS estimate revision for DARE?▾
The most recent revision occurred on 2026-05-19, when analysts adjusted the next-year EPS growth estimate from 45.45% to 49.30%.
What sector and industry does Dare Bioscience Inc belong to?▾
Dare Bioscience Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. DARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Dare Bioscience Inc (DARE) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports